Evaluation of miRNA -210 as prognostic marker of pre-eclampsia
Not Applicable
- Conditions
- Health Condition 1: - Health Condition 2: O00-O9A- Pregnancy, childbirth and the puerperium
- Registration Number
- CTRI/2023/10/059019
- Lead Sponsor
- DR KOTA SAI MEGHANA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Any pregnant woman with BP more than or equal to 140/90mmhg with two readings measured 6 hours apart with significant proteinuria (more than or equal to 300 mg of protein in a 24hr urine specimen or more than or equal to 1+ by dipstick) following 20 weeks of gestation in a previously normotensive woman
2Pregnant women age more than or equal to 18
3Singleton pregnancy
4Prenatal care at BLDE
Exclusion Criteria
1 Any congenital fetal malformations or chromosomal abnormalities
2 Chronic Hypertension
3 Twins with pre eclampsia
4 Renal disease with pre eclampsia
5 Cardiac disease with pre eclampsia
6 Recent infection
7 APLA Syndrome
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the upregulation of miRNA 210 gene in pre-eclamptic women compared to normal healthy pregnant womenTimepoint: 2 years
- Secondary Outcome Measures
Name Time Method To correlate the severity of pre-eclampsia in pregnant women with the gene expression. <br/ ><br>To correlate the fetal outcome with respect to fetal growth restriction, oligohydramnios, low birth weight, neonatal asphyxia, NICU admission. <br/ ><br>Timepoint: 2 years